Waters, 186003949, ACQUITY UPLC Oligonucleotide BEH C18 Column, 130Å, 1.7 µm, 2.1 mm X 50 mm, 1K - 30K, 1/pk

Waters Oligonucleotide Separation Technology (OST) columns are used to separate detritylated synthetic oligonucleotides based on ion-pair, reversed-phase chromatography. Each column is QC tested using Waters MassPrep OST standards to ensure repeatable performance for your most demanding oligonucleotide assays.acqui

Specifications
Chemistry: C18
Separation Mode: Reversed Phase
Particle Substrate: Hybrid
pH Range Min: 1 pH
pH Range Max: 12 pH
Endcapped: Yes
Silanol Activity: Low
Molecular Weight Range Min: 1000
Molecular Weight Range Max: 30000
Particle Shape: Spherical
Particle Size: 1.7 µm
Endfitting Type: Parker-style
Pore Size: 130 Å
QC Tested: Oligonucleotide
Format: Column
System: UPLC, UHPLC
Particle Technology: BEH
USP Classification: L1
Inner Diameter: 2.1 mm
Length: 50 mm
Carbon Load: 18 %
UNSPSC: 41115709
Application: Oligonucleotide, Gene Therapeutics
Brand: ACQUITY UPLC
Product Type: Columns
Units per Package: 1 pk

Additional Information
ACQUITY UPLC Oligonucleotide BEH C18 Column, 130Å, 1.7 µm, 2.1 mm X 50 mm, 1K - 30K, 1/pk Ideally suited for the characterization of oligonucleotides by ion-pair, reversed-phase chromatography, the 1.7 µm ACQUITY UPLC Oligonucleotide BEH C18 Columns deliver outstanding peak shape, sample resolution, and extended column life. Designed for use with an ACQUITY UPLC System, the ACQUITY UPLC Oligonucleotide BEH C18 Columns are able to resolve large oligonucleotide sequences by leveraging the resolving power of sub-3 µm, BEH Technology particles. Designed specifically for the UPLC analysis of synthetic oligonucleotides, the Waters ACQUITY UPLC Oligonucleotide BEH C18 Columns were designed in response to in-depth studies of existing technologies of this application area. Waters designed this flexible separation chemistry technology to enable researchers to make groundbreaking discoveries that lead to drug therapies or diagnostic reagents. The ACQUITY UPLC Oligonucleotide BEH C18 Columns rely on the separation method based on highly efficient ion-pairing reversed-phase (IR-RP) chromatography of the ‘tritily-off’ synthetic oligonucleotide species, where the oligonucleotide is detritylated at the last step of the synthesis. The ACQUITY UPLC Oligonucleotide BEH C18 Columns offer a new standard of synthetic oligonucleotide purification by providing the highest level of purification of the product without compromising product recovery when compared with gel electrophoresis, desalting, cartridges, or ion-exchange chromatography. They are well suited for the purification and analysis of the sensitive DNA or RNA-based oligonucleotide products. Similar to the Waters XBridge OST C18 columns and often used in conjunction with the MassPREP Oligonucleotide Standard , the ACQUITY UPLC Oligonucleotide BEH C18 Columns also provide exceptional packed bed stability over repeated conditions of increased temperatures and high pH conditions compared to silica-based lab equipment .

FAQ
How is Quality Control assured? Our products are manufactured in the cGMP, ISO 9001 conditions, and each item is inspected and tested to ensure that the standards are met and optimal performance is guaranteed for your scientists. Each ACQUITY UPLC BEH Columns also comes with a Certificate Analysis and Performance Test Chromatogram integrated within the eCord Intelligent Chip. The Performance Test Chromatogram is specific to individual columns, containing gel batch number, column serial number, USP Plate number, USP tailing factor, capacity factor, and chromatographic conditions. The Certificate of Analysis is specified to each batch of packing material and includes the gel batch number, analysis of unbonded particles, analysis of bonded particles, and chromatographic results and conditions. What is BEH Technology? One of the key enablers behind UPLC technology, the 1.7 µm BEH (Ethylene Bridged Hybrid) particle is available in varying pore sizes and bonded phases, allowing both reversed-phase and hydrophilic interaction chromatography. The technology applies to a range of small molecule to large molecule biopharmaceutical analysis.
Hybrid particle technology has intrinsic chemical stability, allowing for a wider usable pH range [pH 1-12]. This also enables a versatile, robust separation technology for method development.
The BEH particle technology is available in a variety of HPLC particle sizes [2.5, 3.5, 5, and 10 µm] which allows for a seamless transition between HPLC and UPLC technology platforms.